Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells
Authors:
- 1 January 2017
- journal article
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 65 (8) , 768-775
Abstract
Antimetabolite drugs, including the adenosine deaminase inhibitor cladribine, have been shown to induce apoptosis in a variety of cancer cells, and have been widely used in clinical trials of various cancers in conjunction with tyrosine kinase inhibitors (TKIs). Combination treatment with cladribine and gefitinib or dasatinib is expected to have a synergistic inhibitory effect on breast cancer cell growth. Our results demonstrated that the combination treatment had synergistic activity against human breast cancer (MCF-7) cells, enhanced G/M cell arrest and reactive oxygen species (ROS) generation, and increased the loss of mitochondrial membrane potential and cell apoptosis. In addition, the combination treatment decreased Bcl-2 expression. Our results demonstrated that cladribine in combination with gefitinib or dasatinib exerted synergistic anticancer effects on MCF-7 cells by inducing cell cycle arrest, ROS production and apoptosis through the mitochondria-mediated intrinsic pathway.Keywords
This publication has 29 references indexed in Scilit:
- Emerging functional roles of nuclear receptors in breast cancerJournal of Molecular Endocrinology, 2017
- An overview of the effective combination therapies for the treatment of breast cancerBiomaterials, 2016
- The prognostic value of phosphorylated Akt in breast cancer: a systematic reviewScientific Reports, 2015
- Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cellsMolecular Cancer, 2012
- Radiation Therapy for Early-Stage Breast Cancer after Breast-Conserving SurgeryNew England Journal of Medicine, 2009
- Systems biology and combination therapy in the quest for clinical efficacyNature Chemical Biology, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Consensus StatementEndocrine-Related Cancer, 2005
- Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity?Breast Cancer Research and Treatment, 1995
- Surgical Adjuvant Chemotherapy in Cancer of the BreastAnnals of Surgery, 1968